{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:30:32Z","timestamp":1790307032921,"version":"4.1.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T00:00:00Z","timestamp":1536883200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00467-018-4061-9","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T13:45:33Z","timestamp":1536932733000},"page":"1655-1669","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["An update on LDL apheresis for nephrotic syndrome"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3892-8376","authenticated-orcid":false,"given":"Rupesh","family":"Raina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Krishnappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,14]]},"reference":[{"key":"4061_CR1","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S0140-6736(76)91736-0","volume":"1","author":"PJ Lupien","year":"1976","unstructured":"Lupien PJ, Moorjani S, Awad J (1976) A new approach to the management of familial hypercholesterolaemia: removal of plasma-cholesterol based on the principle of affinity chromatography. Lancet 1:1261\u20131265","journal-title":"Lancet"},{"key":"4061_CR2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0140-6736(81)91213-7","volume":"2","author":"W Stoffel","year":"1981","unstructured":"Stoffel W, Borberg H, Greve V (1981) Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet 2:1005\u20131007","journal-title":"Lancet"},{"key":"4061_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0021-9150(02)00251-4","volume":"167","author":"GR Thompson","year":"2003","unstructured":"Thompson GR (2003) LDL apheresis. Atherosclerosis 167:1\u201313","journal-title":"Atherosclerosis"},{"key":"4061_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10157-007-0003-8","volume":"12","author":"S Kobayashi","year":"2008","unstructured":"Kobayashi S (2008) Applications of LDL-apheresis in nephrology. Clin Exp Nephrol 12:9\u201315","journal-title":"Clin Exp Nephrol"},{"key":"4061_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrneph.2017.155","volume":"14","author":"S Agrawal","year":"2018","unstructured":"Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE (2018) Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 14:57\u201370","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"4061_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/jcdd5020027","volume":"5","author":"Ulrich Julius","year":"2018","unstructured":"Julius U (2018) Current role of lipoprotein apheresis in the treatment of high-risk patients. J Cardiovasc Dev Dis. \n                    https:\/\/doi.org\/10.3390\/jcdd5020027","journal-title":"Journal of Cardiovascular Development and Disease"},{"key":"4061_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10157-014-0996-8","volume":"19","author":"E Muso","year":"2015","unstructured":"Muso E, Mune M, Hirano T, Hattori M, Kimura K, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Yuzawa Y, Takemura T, Sugiyama S, Nishizawa Y, Ogahara S, Yorioka N, Sakai S, Ogura Y, Yukawa S, Iino Y, Imai E, Matsuo S, Saito T (2015) Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study. Clin Exp Nephrol 19:379\u2013386","journal-title":"Clin Exp Nephrol"},{"key":"4061_CR8","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(82)91513-6","volume":"2","author":"JF Moorhead","year":"1982","unstructured":"Moorhead JF, Chan MK, El-Nahas M, Varghese Z (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2:1309\u20131311","journal-title":"Lancet"},{"key":"4061_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/ki.1988.51","volume":"33","author":"BL Kasiske","year":"1988","unstructured":"Kasiske BL, O'Donnell MP, Cleary MP, Keane WF (1988) Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 33:667\u2013672","journal-title":"Kidney Int"},{"key":"4061_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00125-003-1099-3","volume":"46","author":"T Ota","year":"2003","unstructured":"Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K (2003) Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 46:843\u2013851","journal-title":"Diabetologia"},{"key":"4061_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1159\/000089905","volume":"25","author":"C Li","year":"2005","unstructured":"Li C, Lim SW, Choi BS, Lee SH, Cha JH, Kim IS, Kim J, Yang CW (2005) Inhibitory effect of pravastatin on transforming growth factor beta1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropathy. Am J Nephrol 25:611\u2013620","journal-title":"Am J Nephrol"},{"key":"4061_CR12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1681\/ASN.2005050571","volume":"17","author":"S Shibata","year":"2006","unstructured":"Shibata S, Nagase M, Fujita T (2006) Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 17:754\u2013764","journal-title":"J Am Soc Nephrol"},{"key":"4061_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/ndt\/gfn528","volume":"24","author":"FC Cormack-Aboud","year":"2009","unstructured":"Cormack-Aboud FC, Brinkkoetter PT, Pippin JW, Shankland SJ, Durvasula RV (2009) Rosuvastatin protects against podocyte apoptosis in vitro. Nephrol Dial Transplant 24:404\u2013412","journal-title":"Nephrol Dial Transplant"},{"key":"4061_CR14","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/ndt\/17.5.798","volume":"17","author":"T Nakamura","year":"2002","unstructured":"Nakamura T, Ushiyama C, Hirokawa K, Osada S, Inoue T, Shimada N, Koide H (2002) Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 17:798\u2013802","journal-title":"Nephrol Dial Transplant"},{"key":"4061_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/jcp.2003.012989","volume":"57","author":"VG Athyros","year":"2004","unstructured":"Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M (2004) The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57:728\u2013734","journal-title":"J Clin Pathol"},{"key":"4061_CR16","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1681\/ASN.2006010012","volume":"17","author":"S Sandhu","year":"2006","unstructured":"Sandhu S, Wiebe N, Fried LF, Tonelli M (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17:2006\u20132016","journal-title":"J Am Soc Nephrol"},{"key":"4061_CR17","doi-asserted-by":"publisher","unstructured":"Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L (2013) Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev:Cd005425. \n                    https:\/\/doi.org\/10.1002\/14651858.CD005425.pub","DOI":"10.1002\/14651858.CD005425.pub"},{"key":"4061_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s10157-013-0930-5","volume":"18","author":"E Muso","year":"2014","unstructured":"Muso E (2014) Beneficial effect of LDL-apheresis in refractory nephrotic syndrome. Clin Exp Nephrol 18:286\u2013290","journal-title":"Clin Exp Nephrol"},{"key":"4061_CR19","first-page":"1153","volume":"30","author":"K Tojo","year":"1988","unstructured":"Tojo K, Sakai S, Miyahara T (1988) Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). Nihon Jinzo Gakkai shi 30:1153\u20131160","journal-title":"Nihon Jinzo Gakkai shi"},{"key":"4061_CR20","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1053\/j.ajkd.2003.08.012","volume":"42","author":"M Hattori","year":"2003","unstructured":"Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, Fukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K (2003) A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 42:1121\u20131130","journal-title":"Am J Kidney Dis"},{"key":"4061_CR21","first-page":"1","volume":"50","author":"K Yokoyama","year":"1998","unstructured":"Yokoyama K, Sakai S, Sigematsu T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T (1998) LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. Clin Nephrol 50:1\u20137","journal-title":"Clin Nephrol"},{"key":"4061_CR22","first-page":"257","volume":"9","author":"E Muso","year":"1994","unstructured":"Muso E, Yashiro M, Matsushima M, Yoshida H, Sawanishi K, Sasayama S (1994) Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis? Nephrol Dial T ransplant 9:257\u2013264","journal-title":"Nephrol Dial T ransplant"},{"key":"4061_CR23","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000046112","volume":"89","author":"E Muso","year":"2001","unstructured":"Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Takemura T, Miki S, Kuwahara T, Takamitsu Y, Tsubakihara Y (2001) Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 89:408\u2013415","journal-title":"Nephron"},{"key":"4061_CR24","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1046\/j.1523-1755.1999.07130.x","volume":"71","author":"E Muso","year":"1999","unstructured":"Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Miki S, Kuwahara T, Takamitsu Y, Takemura T, Tsubakihara Y (1999) Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Kidney Int Suppl 71:S122\u2013S125","journal-title":"Kidney Int Suppl"},{"key":"4061_CR25","doi-asserted-by":"publisher","first-page":"341","DOI":"10.5414\/CNP67341","volume":"67","author":"E Muso","year":"2007","unstructured":"Muso E, Mune M, Yorioka N, Nishizawa Y, Hirano T, Hattori M, Sugiyama S, Watanabe T, Kimura K, Yokoyama H, Sato H, Saito T (2007) Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol 67:341\u2013344","journal-title":"Clin Nephrol"},{"key":"4061_CR26","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/MNH.0b013e32833aa4ac","volume":"19","author":"IA Bobulescu","year":"2010","unstructured":"Bobulescu IA (2010) Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens 19:393\u2013402","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"4061_CR27","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrneph.2009.184","volume":"5","author":"XZ Ruan","year":"2009","unstructured":"Ruan XZ, Varghese Z, Moorhead JF (2009) An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol 5:713\u2013721","journal-title":"Nat Rev Nephrol"},{"key":"4061_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1046\/j.1365-2796.1996.501855000.x","volume":"240","author":"KR Balson","year":"1996","unstructured":"Balson KR, Niall JF, Best JD (1996) Glomerular lipid deposition and proteinuria in a patient with familial dysbetalipoproteinaemia. J Intern Med 240:157\u2013159","journal-title":"J Intern Med"},{"key":"4061_CR29","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0272-6386(12)80055-2","volume":"16","author":"JC Jennette","year":"1990","unstructured":"Jennette JC, Falk RJ (1990) Adult minimal change glomerulopathy with acute renal failure. Am J Kidney Dis 16:432\u2013437","journal-title":"Am J Kidney Dis"},{"key":"4061_CR30","first-page":"404","volume":"61","author":"AB Magil","year":"1989","unstructured":"Magil AB, Cohen AH (1989) Monocytes and focal glomerulosclerosis. LabInvest 61:404\u2013409","journal-title":"LabInvest"},{"key":"4061_CR31","first-page":"540","volume":"38","author":"T Hovig","year":"1978","unstructured":"Hovig T, Blomhoff JP, Holme R, Flatmark A, Gjone E (1978) Plasma lipoprotein alterations and morphologic changes with lipid deposition in the kidney of patients with hepatorenal syndrome. Lab Investig 38:540\u2013549","journal-title":"Lab Investig"},{"key":"4061_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/ki.1978.32","volume":"13","author":"MC Gubler","year":"1978","unstructured":"Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R (1978) Early renal changes in hemizygous and heterozygous patients with Fabry\u2019s disease. Kidney Int 13:223\u2013235","journal-title":"Kidney Int"},{"key":"4061_CR33","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/0020-711X(78)90040-X","volume":"9","author":"RE Druilhet","year":"1978","unstructured":"Druilhet RE, Overturf ML, Kirkendall WM (1978) Cortical and medullary lipids of normal and nephrosclerotic human kidney. Int J BioChemiPhysics 9:729\u2013734","journal-title":"Int J BioChemiPhysics"},{"key":"4061_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/j.ajkd.2005.12.031","volume":"47","author":"R Sam","year":"2006","unstructured":"Sam R, Wu H, Yue L, Mazzone T, Schwartz MM, Arruda JA, Dunea G, Singh AK (2006) Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis 47:539\u2013548","journal-title":"Am J Kidney Dis"},{"key":"4061_CR35","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1111\/j.1523-1755.2005.00325.x","volume":"67","author":"AC Johnson","year":"2005","unstructured":"Johnson AC, Stahl A, Zager RA (2005) Triglyceride accumulation in injured renal tubular cells: alterations in both synthetic and catabolic pathways. Kidney Int 67:2196\u20132209","journal-title":"Kidney Int"},{"key":"4061_CR36","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1073\/pnas.0630588100","volume":"100","author":"LL Listenberger","year":"2003","unstructured":"Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, Ory DS, Schaffer JE (2003) Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 100:3077\u20133082","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4061_CR37","first-page":"E708","volume":"273","author":"K Koyama","year":"1997","unstructured":"Koyama K, Chen G, Lee Y, Unger RH (1997) Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Phys 273:E708\u2013E713","journal-title":"Am J Phys"},{"key":"4061_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/ndt\/gfn436","volume":"24","author":"T Feldkamp","year":"2009","unstructured":"Feldkamp T, Weinberg JM, Horbelt M, Von Kropff C, Witzke O, Nurnberger J, Kribben A (2009) Evidence for involvement of nonesterified fatty acid-induced protonophoric uncoupling during mitochondrial dysfunction caused by hypoxia and reoxygenation. Nephrol Dial Transplant 24:43\u201351","journal-title":"Nephrol Dial Transplant"},{"key":"4061_CR39","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/sj.ki.5001834","volume":"70","author":"JM Weinberg","year":"2006","unstructured":"Weinberg JM (2006) Lipotoxicity. Kidney Int 70:1560\u20131566","journal-title":"Kidney Int"},{"key":"4061_CR40","first-page":"F465","volume":"290","author":"T Feldkamp","year":"2006","unstructured":"Feldkamp T, Kribben A, Roeser NF, Senter RA, Weinberg JM (2006) Accumulation of nonesterified fatty acids causes the sustained energetic deficit in kidney proximal tubules after hypoxia-reoxygenation. Am J Phys Renal Phys 290:F465\u2013F477","journal-title":"Am J Phys Renal Phys"},{"key":"4061_CR41","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/00041433-200306000-00008","volume":"14","author":"JE Schaffer","year":"2003","unstructured":"Schaffer JE (2003) Lipotoxicity: when tissues overeat. Curr Opin Lipidol 14:281\u2013287","journal-title":"Curr Opin Lipidol"},{"key":"4061_CR42","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/sj.ki.5000089","volume":"69","author":"J Axelsson","year":"2006","unstructured":"Axelsson J, Bergsten A, Qureshi AR, Heimburger O, Barany P, Lonnqvist F, Lindholm B, Nordfors L, Alvestrand A, Stenvinkel P (2006) Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 69:596\u2013604","journal-title":"Kidney Int"},{"key":"4061_CR43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.02790806","volume":"2","author":"M Mitsnefes","year":"2007","unstructured":"Mitsnefes M, Kartal J, Khoury P, Daniels S (2007) Adiponectin in children with chronic kidney disease: role of adiposity and kidney dysfunction. Clin J Am Soc Nephrol 2:46\u201350","journal-title":"Clin J Am Soc Nephrol"},{"key":"4061_CR44","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2174\/138161212799436593","volume":"18","author":"LS Capettini","year":"2012","unstructured":"Capettini LS, Montecucco F, Mach F, Stergiopulos N, Santos RA, da Silva RF (2012) Role of renin-angiotensin system in inflammation, immunity and aging. Curr Pharm Des 18:963\u2013970","journal-title":"Curr Pharm Des"},{"key":"4061_CR45","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1681\/ASN.2004080629","volume":"16","author":"B Bussolati","year":"2005","unstructured":"Bussolati B, Deregibus MC, Fonsato V, Doublier S, Spatola T, Procida S, Di Carlo F, Camussi G (2005) Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase\/AKT-signaling pathway. J Am Soc Nephrol 16:1936\u20131947","journal-title":"J Am Soc Nephrol"},{"key":"4061_CR46","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1172\/JCI79641","volume":"125","author":"JJ Chung","year":"2015","unstructured":"Chung JJ, Huber TB, Godel M, Jarad G, Hartleben B, Kwoh C, Keil A, Karpitskiy A, Hu J, Huh CJ, Cella M, Gross RW, Miner JH, Shaw AS (2015) Albumin-associated free fatty acids induce macropinocytosis in podocytes. J Clin Invest 125:2307\u20132316","journal-title":"J Clin Invest"},{"key":"4061_CR47","doi-asserted-by":"publisher","first-page":"e54817","DOI":"10.1371\/journal.pone.0054817","volume":"8","author":"K Okamura","year":"2013","unstructured":"Okamura K, Dummer P, Kopp J, Qiu L, Levi M, Faubel S, Blaine J (2013) Endocytosis of albumin by podocytes elicits an inflammatory response and induces apoptotic cell death. PLoS One 8:e54817","journal-title":"PLoS One"},{"key":"4061_CR48","first-page":"394","volume":"110","author":"N Yoshikawa","year":"1986","unstructured":"Yoshikawa N, Ito H, Akamatsu R, Hazikano H, Okada S, Matsuo T (1986) Glomerular podocyte vacuolation in focal segmental glomerulosclerosis. Arch Pathol Lab Med 110:394\u2013398","journal-title":"Arch Pathol Lab Med"},{"key":"4061_CR49","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/00002480-200005000-00011","volume":"46","author":"IS Jovin","year":"2000","unstructured":"Jovin IS, Taborski U, Muller-Berghaus G (2000) Analysis of the long-term efficacy and selectivity of immunoadsorption columns for low density lipoprotein apheresis. ASAIO J 46:298\u2013300","journal-title":"ASAIO J"},{"key":"4061_CR50","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/0002-9149(92)90352-Y","volume":"70","author":"BR Gordon","year":"1992","unstructured":"Gordon BR, Kelsey SF, Bilheimer DW, Brown DC, Dau PC, Gotto AM Jr, Illingworth DR, Jones PH, Leitman SF, Prihoda JS et al (1992) Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group. Am J Cardiol 70:1010\u20131016","journal-title":"Am J Cardiol"},{"key":"4061_CR51","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0009-3084(94)90152-X","volume":"67-68","author":"VW Armstrong","year":"1994","unstructured":"Armstrong VW, Schuff-Werner P, Eisenhauer T, Helmhold M, Stix M, Seidel D (1994) Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp (a) levels. Chem Phys Lipids 67-68:315\u2013321","journal-title":"Chem Phys Lipids"},{"key":"4061_CR52","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF01728226","volume":"65","author":"T Eisenhauer","year":"1987","unstructured":"Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D (1987) Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. Klin Wochenschr 65:161\u2013168","journal-title":"Klin Wochenschr"},{"key":"4061_CR53","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1046\/j.1365-2362.2001.00758.x","volume":"31","author":"V Schettler","year":"2001","unstructured":"Schettler V, Monazahian M, Wieland E, Ramadori G, Grunewald RW, Thomssen R, Muller GA (2001) Reduction of hepatitis C virus load by H.E.L.P.-LDL apheresis. Eur J Clin Investig 31:154\u2013155","journal-title":"Eur J Clin Investig"},{"key":"4061_CR54","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0021-9150(01)00633-5","volume":"158","author":"PM Moriarty","year":"2001","unstructured":"Moriarty PM, Gibson CA, Shih J, Matias MS (2001) C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis 158:495\u2013498","journal-title":"Atherosclerosis"},{"key":"4061_CR55","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1526-0968.1999.00162.x","volume":"3","author":"T Bosch","year":"1999","unstructured":"Bosch T, Lennertz A, Kordes B, Samtleben W (1999) Low density lipoprotein hemoperfusion by direct adsorption of lipoproteins from whole blood (DALI apheresis): clinical experience from a single center. Ther Apher 3:209\u2013213","journal-title":"Ther Apher"},{"key":"4061_CR56","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/j.1525-1594.1997.tb00443.x","volume":"21","author":"T Bosch","year":"1997","unstructured":"Bosch T, Schmidt B, Kleophas W, Otto V, Samtleben W (1997) LDL hemoperfusion\u2014a new procedure for LDL apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients. Artif Organs 21:1060\u20131065","journal-title":"Artif Organs"},{"key":"4061_CR57","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s00540-008-0726-z","volume":"23","author":"J Oto","year":"2009","unstructured":"Oto J, Suga K, Matsuura S, Kondo S, Ohnishi Y, Inui D, Imanaka H, Kagami S, Nishimura M (2009) Low-density lipoprotein apheresis in a pediatric patient with refractory nephrotic syndrome due to focal segmental glomerulosclerosis. J Anesth 23:284\u2013287","journal-title":"J Anesth"},{"key":"4061_CR58","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00467-006-0426-6","volume":"22","author":"Y Kawasaki","year":"2007","unstructured":"Kawasaki Y, Suzuki S, Matsumoto A, Takano K, Suyama K, Hashimoto K, Suzuki J, Suzuki H, Hosoya M (2007) Long-term efficacy of low-density lipoprotein apheresis for focal and segmental glomerulosclerosis. Pediatr Nephrol 22:889\u2013892","journal-title":"Pediatr Nephrol"},{"key":"4061_CR59","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/BF00864397","volume":"7","author":"M Hattori","year":"1993","unstructured":"Hattori M, Ito K, Kawaguchi H, Tanaka T, Kubota R, Khono M (1993) Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis. Pediatr Nephrol 7:196\u2013198","journal-title":"Pediatr Nephrol"},{"key":"4061_CR60","unstructured":"Munoz M, Lumbreras J, Madrid A, Lara LE, Chocron S, Vilalta R, Ariceta G (2017) Complete remission of post-transplant recurrence of focal segmental glomerulosclerosis in children with the use of LDL-apheresis therapy: case report. Pediatric Transplantation. Wiley, Hoboken, p 63"},{"key":"4061_CR61","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00467-006-0371-4","volume":"22","author":"S Ito","year":"2007","unstructured":"Ito S, Machida H, Inaba A, Harada T, Okuyama K, Nakamura T, Aihara Y, Yokota S (2007) Amelioration of steroids and cyclosporine-resistant nephrotic syndrome by pravastatin. Pediatr Nephrol 22:603\u2013606","journal-title":"Pediatr Nephrol"},{"key":"4061_CR62","first-page":"193","volume":"337","author":"K Tojo","year":"1990","unstructured":"Tojo K, Sakai S, Miyahara T (1990) Therapeutic trial of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). Prog Clin Biol Res 337:193\u2013194","journal-title":"Prog Clin Biol Res"},{"issue":"1","key":"4061_CR63","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s10157-014-1030-x","volume":"19","author":"Kenji Ishikura","year":"2015","unstructured":"Ishikura K, Matsumoto S, Sako M, Tsuruga K, Nakanishi K, Kamei K, Saito H, Fujinaga S, Hamasaki Y, Chikamoto H, Ohtsuka Y, Komatsu Y, Ohta T, Nagai T, Kaito H, Kondo S, Ikezumi Y, Tanaka S, Kaku Y, Iijima K, Japanese Society for Pediatric N (2015) Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. Clin Exp Nephrol 19:6\u201333","journal-title":"Clinical and Experimental Nephrology"},{"key":"4061_CR64","unstructured":"FDA (2018) Liposorber\u00ae LA-15 System FDA Executive Summary. Available from\u00a0\n                    https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/PediatricAdvisoryCommittee\/UCM601669.pdf\n                    \n                  . Accessed 20 April 2018"},{"key":"4061_CR65","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.2169\/internalmedicine.51.7204","volume":"51","author":"Y Sato","year":"2012","unstructured":"Sato Y, Tsunoda S, Nozue T, Pan Q, Wakasugi H, Yoshimura A (2012) Low-density lipoprotein apheresis therapy for steroid- and cyclosporine-resistant idiopathic membranous nephropathy. Intern Med 51:2597\u20132602","journal-title":"Intern Med"},{"key":"4061_CR66","doi-asserted-by":"publisher","first-page":"423","DOI":"10.5414\/CNP65423","volume":"65","author":"T Kobayashi","year":"2006","unstructured":"Kobayashi T, Ando Y, Umino T, Miyata Y, Muto S, Hironaka M, Asano Y, Kusano E (2006) Complete remission of minimal-change nephrotic syndrome induced by apheresis monotherapy. Clin Nephrol 65:423\u2013426","journal-title":"Clin Nephrol"},{"key":"4061_CR67","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1159\/000045774","volume":"86","author":"T Iwahori","year":"2000","unstructured":"Iwahori T, Yoshida M (2000) Low-density lipoprotein apheresis can improve type AA systemic amyloidosis. Nephron 86:248\u2013250","journal-title":"Nephron"},{"key":"4061_CR68","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4009\/jsdt.27.233","volume":"27","author":"T Shibata","year":"1994","unstructured":"Shibata T, Okabe E, Sumie A, Ishii T, Tomo T, Yasumori R, Nasu M, Nomura Y (1994) A case of nephrotic syndrome due to IgA nephropathy complicated by acute renal failure and ameriolated by low density lipoprotein (LDL) apheresis. Nihon Toseki Igakkai Zasshi 27:233\u2013236","journal-title":"Nihon Toseki Igakkai Zasshi"},{"key":"4061_CR69","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/ndt\/15.2.235","volume":"15","author":"S Daimon","year":"2000","unstructured":"Daimon S, Saga T, Nakayama M, Nomura Y, Chikaki H, Dan K, Koni I (2000) Dextran sulphate cellulose columns for the treatment of nephrotic syndrome due to inactive lupus nephritis. Nephrol Dial Transplant 15:235\u2013238","journal-title":"Nephrol Dial Transplant"},{"key":"4061_CR70","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1053\/j.ajkd.2014.09.028","volume":"65","author":"N Shiraishi","year":"2015","unstructured":"Shiraishi N, Kitamura K, Hayata M, Ogata T, Tajiri-Okamura K, Nakayama Y, Kohda Y, Tomita K, Mukoyama M (2015) Low-density lipoprotein apheresis for proteinuria in lupus nephritis with intraglomerular foam cells containing cholesterol crystals. Am J Kidney Dis 65:490\u2013493","journal-title":"Am J Kidney Dis"},{"key":"4061_CR71","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1097\/01.ASN.0000113552.59155.72","volume":"15","author":"RG Ruf","year":"2004","unstructured":"Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M, Zalewski I, Imm A, Ruf EM, Mucha B, Bagga A, Neuhaus T, Fuchshuber A, Bakkaloglu A, Hildebrandt F (2004) Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 15:722\u2013732","journal-title":"J Am Soc Nephrol"},{"key":"4061_CR72","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000437338","volume":"5","author":"E Muso","year":"2015","unstructured":"Muso E, Mune M, Hirano T, Hattori M, Kimura K, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Takemura T, Yuzawa Y, Ogahara S, Sugiyama S, Iino Y, Sakai S, Ogura Y, Yukawa S, Nishizawa Y, Yorioka N, Imai E, Matsuo S, Saito T (2015) A prospective observational survey on the long-term effect of LDL apheresis on drug-resistant nephrotic syndrome. Nephron Extra 5:58\u201366","journal-title":"Nephron Extra"},{"key":"4061_CR73","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/nep.12711","volume":"21","author":"A Tanaka","year":"2016","unstructured":"Tanaka A, Nakamura T, Sato E, Node K (2016) Impact of low-density lipoprotein apheresis for nephrotic syndrome in a patient with immunoglobulin M nephropathy. Nephrology 21:1073\u20131074","journal-title":"Nephrology"},{"key":"4061_CR74","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1046\/j.1365-2362.2000.00716.x","volume":"30","author":"P Stenvinkel","year":"2000","unstructured":"Stenvinkel P, Alvestrand A, Angelin B, Eriksson M (2000) LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. Eur J Clin Investig 30:866\u2013870","journal-title":"Eur J Clin Investig"},{"key":"4061_CR75","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1046\/j.1523-1755.1999.07102.x","volume":"71","author":"C Brunton","year":"1999","unstructured":"Brunton C, Varghese Z, Moorhead JF (1999) Lipopheresis in the nephrotic syndrome. Kidney Int Suppl 71:S6\u2013S9","journal-title":"Kidney Int Suppl"},{"key":"4061_CR76","first-page":"46","volume":"38","author":"T Okada","year":"1996","unstructured":"Okada T, Takahashi H, Ogura M, Nakao T, Shimizu T (1996) Complete remission of steroid-resistant minimal-change nephrotic syndrome by cyclosporin after additional low-density lipoprotein apheresis treatment. Nihon Jinzo Gakkai shi 38:46\u201351","journal-title":"Nihon Jinzo Gakkai shi"},{"key":"4061_CR77","unstructured":"FDA (2018) FDA Listing of CDRH Humanitarian Device Exemptions.\u00a0Available from\u00a0\n                    https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfhde\/hde.cfm?id=H170002\n                    \n                  . Accessed 20 April 2018"},{"key":"4061_CR78","first-page":"1","volume":"2018","author":"A Sannomiya","year":"2018","unstructured":"Sannomiya A, Murakami T, Koyama I, Nitta K, Nakajima I, Fuchinoue S (2018) Preoperative low-density lipoprotein apheresis for preventing recurrence of focal segmental glomerulosclerosis after kidney transplantation. J Transp Secur 2018:1\u20135","journal-title":"J Transp Secur"},{"key":"4061_CR79","unstructured":"FDA (2013) A patient guide to the Liposorber LA-15 System. Available from \n                    https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf12\/H120005D.pdf\n                    \n                  . Accessed 20 April 2018"},{"key":"4061_CR80","unstructured":"Blue Cross Blue Shield of North Carolina\u00a0(2013) Blue Cross Blue Shield of North Carolina Corporate Medical Policy: lipid apheresis. Available from\u00a0\n                    https:\/\/www.bluecrossnc.com\/sites\/default\/files\/document\/attachment\/services\/public\/pdfs\/medicalpolicy\/lipid_apheresis.pdf\n                    \n                  . Accessed 23 April 2018."},{"key":"4061_CR81","unstructured":"NIH (2014) Post approval study of Liposorber LA-15 System for the treatment of focal segmental glomerulosclerosis in children. Available from \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02235857\n                    \n                  . April 28 2018"},{"key":"4061_CR82","unstructured":"FDA (2013) LIPOSORBER LA-15 SYSTEM operator\u2019s manual. Available from \n                    www.accessdata.fda.gov\/cdrh_docs\/pdf12\/H120005C.pdf\n                    \n                   April 26 2018"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4061-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-4061-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4061-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T02:02:08Z","timestamp":1570068128000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-4061-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,14]]},"references-count":82,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["4061"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-4061-9","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,14]]},"assertion":[{"value":"8 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}